Denver, Colorado, Nov. 28, 2022 (GLOBE NEWSWIRE) -- GATTONI Medical Aesthetics & Wellness is a Medical spa in Denver, CO, that has mastered the art and science of anti-aging and regenerative medicine to deliver an array of services to enhance your health and beauty, including Botox, Dysport, Filler, Kybella, Sculptra, PRX-T33 Treatment, and Women’s Intimate Health.
They have now opened their new clinic in the Cherry Creek area of Denver, Colorado, and offer a range of high-end lip augmentation and Botox treatments to leave you feeling more empowered, more beautiful, and more confident than when you first arrived at their clinic.
Achieve Your Aesthetic and Wellness Goals
GATTONI Medical Aesthetics & Wellness was created by Lea Gattoni, a Master Aesthetic Injector who graduated top of her class at Duke University School of Medicine Physician Assistant Program and later earned a Doctor of Medical Science degree from the University of Lynchburg.
Gattoni and her professional team are dedicated to personalizing treatment to help you achieve your aesthetic and wellness goals and provide a variety of high-quality services using the latest equipment and products from renowned brands.
Their popular Botox and Dysport treatments are the best solutions for treating and preventing wrinkles, fine lines, and deep furrows on your face, and work by relaxing the muscles in your targeted area to create a smoother, more youthful appearance.
Botox is especially effective in treating:
These are the wrinkles that appear between your eyebrows and are usually visible when you furrow your eyebrows.
Botox or Dysport can significantly reduce their appearance and give you an overall more refreshed look.
Lines along the corner of your eyes are known as crow’s feet and can make you appear tired and less youthful.
A Botox treatment only takes 10-15 minutes and can improve the area around your eyes by temporarily reducing these wrinkles.
As people age, they may find that their face becomes less firm and may seem looser in various places, such as around the eyes.
A brow lift will create a more awake appearance by lifting your eyebrows, so you can once again show off your beautiful eyes.
If you are located in Denver, Colorado, and are seeking an effective treatment for the lines on your forehead, then search Botox near me and choose the professional team at GATTONI Medical Aesthetics & Wellness, who can help you achieve a natural and balanced result.
Instead of using fillers to plump and re-shape your lips, Botox or Dysport can give you a fuller smile while also decreasing any fine lines around your mouth.
Botox is used to treat dimples, or the ‘Orange Peel’ look, that can occur on your chin by making the skin appear smoothed and, as a result, more youthful and relaxed.
Platysma muscles are the vertical muscles that are located down the length of your neck and are at their most evident when you clench your jaw.
GATTONI Medical Aesthetics & Wellness will expertly inject Botox into the thick muscular band, which will cause the neck muscles to not be as prominent and give your neck a longer, slimmer, and smoother appearance.
If you no longer want to rely on medication to treat your symptoms, then injecting Botox has been proven to relieve muscular tension and decrease the frequency of migraines and headaches.
To find out more about GATTONI Medical Aesthetics & Wellness and to see a complete list of their aesthetic treatments, please visit their website at https://www.gattonimed.com/.
Source: https://thenewsfront.com/gattoni-medical-aesthetics–wellness-open-new-medical-spa-in-denver-with-high-end-lip-augmentation-and-botox-injectables/
BTIG upgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate's benefit, Gossamer Bio Inc's (NASDAQ: GOSS) TORREY Phase 2 results validated dry powder inhaled (DPI)-administered TKIs in pulmonary arterial hypertension (PAH) as a safe and technically viable approach. But Gossamer's DPI seralutinib does not look like a competitive disease-modifying therapy in PAH, with a PVR reduction of only 14% in the overall study popu
Investing in small-cap stocks can be very risky. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS). Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses.
Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.
Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity.
Only last week, the company was warned about its stock price; this week it's looking at putting a premium on the price of its second FDA-approved drug.
Her friend and co-star John Travolta called her one of the "most special relationships I’ve ever had."
Consider, for instance, Editas Medicine (NASDAQ: EDIT) and BioXcel Therapeutics (NASDAQ: BTAI). Let's consider why Editas Medicine and BioXcel Therapeutics are worth keeping an eye on right now, and whether the potential rewards of investing in these companies outweigh the risks. The company is down by 61% this year, a terrible performance it partly owes to market-wide troubles.
Editas Medicine Inc (NASDAQ: EDIT) announced initial clinical data from the first two sickle cell disease (SCD) patients treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is under development for the treatment of severe sickle cell disease. The clinical data includes safety data from the first two patients and efficacy data from the first patient treated. Both treated patients demonstrated successful neutrophil and platelet engraftment. Additionally, neither patient has experienced any
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
Emergent BioSolutions Inc. (NYSE: EBS) has cleared an important hurdle in a bid to make its opioid overdose antidote available to the public without a doctor’s order. The Gaithersburg company said Tuesday that the Food and Drug Administration has accepted its supplemental new drug application for Narcan Nasal Spray, currently available with a prescription, as an emergency over-the-counter treatment for opioid overdose. The FDA expects to issue its decision of approval or denial March 29, 2023.
Emergent is seeking the U.S. Food and Drug Administration's approval for a prescription-free sale of its nasal spray, Narcan, which is already cleared for the treatment of opioid overdose in the country. The agency will make its decision by March 29 and its priority review status puts Narcan on track to become the first naloxone-based drug to be sold over the counter, Benchmark analyst Robert Wasserman said.
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that the positive results of a Phase 3 clinical trial of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, have been published in Blood,1 the peer-reviewed international medical journal of the American So
More than half of the calories consumed by Americans come from this high-risk food group, which is associated with cognitive decline, cancer and heart disease
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Concurrent studies expand patient enrollment and potential to build positive database … Quoin Pharmaceuticals (NASDAQ:QNRX) has strengthened its cash position and reached several milestones to continue moving its lead candidates and other assets forward. QRX003, Quoin’s investigational product for NS (Netherton syndrome), is being
SimpleImages / GettyThe fight against COVID seems to have fallen into a ping-ponging rhythm at this point, where every step forward seems undercut by one backward. Vaccines are available, and hospitalization rates have fallen dramatically from previous peaks. But just a sliver of eligible Americans have received the most recent bivalent shot, and the specter of a new, somehow worse variant looms large in our collective psyche. Elsewhere, such as in China, we seem to be losing ground to the virus
(Bloomberg) -- China is set to announce a further relaxation of Covid control measures as soon as today — including allowing some infected people to home quarantine as a nationwide policy, and reining in unnecessary testing — according to people familiar with the matter, as the government continues to quickly ease its zero-tolerance strategy amid growing public discontent. Most Read from BloombergTrump Companies Are Convicted in NY Criminal Tax Fraud TrialWall Street Goes Risk Off as Bank CEOs S
Shares of Editas Medicine Inc. rallied 9.3% in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a Phase 1/2 clinical trial assessing its experimental treatment for sickle-cell disease. Editas said the therapy was well-tolerated. "These promising clinical results from the RUBY trial suggest clinical proof of concept for EDIT-301 and support our belief that EDIT-301 can be a clinically differentiated, one-tim
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), Sepsis, and COVID-19 through PREPAiRE, an AI (Artificial Intelligence) powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclin
The actress ended up losing some of her hair during chemotherapy, and now she's celebrating its regrowth